Changing patterns of relapse in Hodgkin's disease. by Duchesne, G. et al.
8©The Macmillan Press Ltd., 1989
Changing patterns of relapse in Hodgkin's disease
G. Duchesne1, J. Crow2, S. Ashley2, M. Bradal & A. Horwichl
Departments of 'Radiotherapy and 2Computing, Institute of Cancer Research and Royal Marsden Hospital,
Downs Road, Sutton, Surrey SM2 5PT, UK.
Summary The patterns of early and late relapses (those occurring later than 3 years after diagnosis) in 432
patients achieving complete remission after treatment for stage I and 11 Hodgkin's disease at the Royal
Marsden Hospital between 1964 and 1983 were studied to identify factors predicting for late relapse. The
incidence of early relapse has fallen progressively in recent treatment eras as staging procedures and
management have improved but in contrast there has been no decrease in the risk of late relapse. The
incidence of late relapse was greater in patients treated with radiotherapy rather than combined modality
therapy (P<0.05). However, patients who were clinically staged and treated with combined modality therapy
retained as high a risk of relapse between 3 and 6 years as in years 2 and 3. The risk of late relapse was also
greater in patients with stage II disease and in those without B symptoms at presentation. Patients falling into
the higher risk categories for late relapse require continued close follow-up beyond 3 years to monitor for
possible relapse.
Early stage Hodgkin's disease has a good prognosis with
modern management and prolonged survival is reported in
about 80% of patients (Hoppe et al., 1982; Peckham et al.,
1982; Tubiana et al., 1984). A number of factors predicting
for relapse and survival have been identified (Yarnold et al.,
1982; Mill & Lee, 1982; Haybittle et al., 1985; Horwich et
al., 1986), which has allowed selection of patients with poor-
risk disease for treatment with combined modality therapy.
Historically the majority of patients who relapsed did so
within 3 years of their primary treatment (Herman et al.,
1985) but the reduction in early relapses with the develop-
ment of better staging and effective therapy has increased the
proportion of patients at risk of late relapse.
We have undertaken a study of all adult patients with
early stage Hodgkin's disease treated at the Royal Marsden
Hospital between 1964 and 1983 to analyse the timing of
relapse with changing management strategies and to identify
factors predicting for late relapse which might determine the
need for long-term follow-up.
Methods
A total of 447 adult patients received their primary treat-
ment for stage I or II Hodgkin's disease at the Royal
Marsden Hospital between 1964 and 1983; the 432 patients
achieving complete remission were selected for study. As
improved staging techniques and treatments were developed
management policies changed. Between 1964 and 1969
patients were staged clinically and the majority received
radiotherapy alone, with a few having additional single-agent
chemotherapy (cyclophosphamide or mustine). Between 1970
and 1974 staging laparotomies were introduced but the
majority of patients continued to receive radiotherapy alone.
Between 1975 and 1980 combination chemotherapy using
MVPP (nitrogen mustard, vinblastine, procarbazine and
prednisolone (Nicholson et al., 1970)) or ChLVPP (chloram-
bucil, vinblastine, procarbazine and prednisolone (Kaye et
al., 1979)) was introduced. From 1980 onwards the use of
staging laparotomies declined as the factors predictive of
occult infradiaphragmatic disease were identified (Brada et
al., 1986): the poor-risk patients were treated electively with
combined modality therapy. The changes in approach to
management are illustrated by the changing proportions of
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patients undergoing staging laparotomy and receiving either
radiotherapy alone or combined modality therapy, as shown
in Table I.
Patients were treated with either radiotherapy alone or in
combined modality treatment together with single agent or
combination chemotherapy. Extended field irradiation was
employed in the majority (96%) of patients to a dose of
40 Gy in 20 daily fractions, reduced to 35 Gy if prior
chemotherapy had been given. If combined modality therapy
was employed, six courses of MVPP or ChLVPP were given,
followed after an interval of 6 weeks by radiotherapy.
Sixteen patients were treated with combination chemo-
therapy alone.
Early relapse was defined .as relapse occurring within 3
years of the date of registration, with late relapses defined as
those occurring beyond 3 years. All patients were followed
for a minimum of 3 years so that all the early relapses were
identified. Actuarial analyses of late relapses were calculated
as the inverse of relapse-free survival for those patients
remaining in remission at 3 years, to allow for the differ-
ences in length of follow-up which might influence the
incidence of late relapse.
The risk of relapse was calculated for patients managed
according to each of the following policies: either clinically
or laparotomy-staged, and receiving either radiotherapy
alone or combined modality therapy. For the purpose of
these analyses the minority of patients receiving chemother-
apy alone were included in the combined modality group, as
patients who received a systemic treatment. The influence of
known prognostic factors (age, stage, sex, syptoms and
Table I The change of management policy with time: number of
patients treated in each time period
Combined
Radiotherapy modality Chemotherapy Total
1964-69 PS 2 0 0
CS 89 16 (3) 0 107
1970-74 PS 70 11 (1) 1
CS 52 8 (2) 1 143
1975-80 PS 67 44 (4) 5 (1)
CS 12 7 (1) 4 (1) 139
1981-83 PS 14 0 0
CS 9 30 (2) 5 58
Total 315 116 16 447
PS =pathological staging; CS =clinical staging. Numbers in
parentheses are patients who did not achieve remission.
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histological type) was evaluated using a log-rank analysis
(Peto et al., 1977), and their effect in determining either early
or late relapse was examined using a x2 analysis. Those
factors having independent prognostic significance for late
relapse were identified using a stratified log-rank multi-
variate analysis.
Results
Incidence of relapse by treatment era
Of the 432 patients achieving complete remission, 149 have
relapsed, 111 within three years and 38 beyond three years.
Figure 1 shows the actuarial relapse-free survival for the
whole population; at 3 years the actuarial rate of relapse was
26.1%, rising to 37.3% by year 12, representing an actuarial
risk of late relapse of 15.7%.
Through successive treatment eras the percentage of
patients suffering early relapse has fallen progressively, being
42.3% in 1964-69, 27.9% in 1970-74, 17.4% in 1975-80 and
8.9% in 1980-83. By contrast the risk of late relapse in the
increasing proportion of patients who remain in remission at
3 years has not declined. The actuarial risk of relapse
between 4 and 12 years was 15.8% for those treated in 1964-
69, 16.8% in 1970-74 and 14.5% in 1975-80. the longest
follow-up for patients treated in 1981-83 was 7 years; up to
this time the actuarial risk of late relapse in this group was
12.2%. There was no statistically significant difference
between the risks of late relapse during the different eras of
treatment.
Influence of management policy on risk of relapse and
duration at risk
The influence of changing management policies on the
incidence of late relapse was examined by management
strategy. Comparison of the actuarial risks of relapse occur-
ring in each treatment group showed a significantly greater
overall risk of relapse in those patients treated with radio-
therapy alone compared with combined modality therapy
(X2 =10.00, P<0.005). The majority of early relapses in
radiotherapy-treated patients were related to staging: the 3-
year actuarial relapse rate in clinically staged patients was
42.3% compared with 14.4% for laparotomy-staged patients
(2 =26.52, P<0.001).
Late relapse was also more common in radiotherapy-
treated patients than in those receiving combined modality
therapy (x2 =4.99, P<0.05) as shown in Figure 2. The lower
risk of late relapse in the combined modality group was due
to the absence of late relapse in laparotomy-staged patients:
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Figure 1 Actuarial relapse-free survival of 432 patients with
stage I and II Hodgkin's disease achieving complete remission.
The actuarial risk of early relapse was 26.1% and that of late
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Figure 2 Actuarial relapse-free survival of 310 patients in
remission at 3 years. Patients treated with combined modality
therapy (CMT) had significantly fewer late relapses than those
treated with radiotherapy alone (RT) (P<0.05). In Figures 2 and
3 only 37 late relapses are illustrated, as the one occurring at 20
years is not included in these analyses.
Table II Univariate analysis of factors predicting for relapse
3-year actuarial 12-year actuarial Log
Factor Level Number relapse rate (%) relapse rate (%)" rankb
Sex Male 253 28.8 15.4 P>0.1
Female 179 22.5 15.7
Age (years) 16-39 311 28.4 12.9 P<0.05
>40 121 19.9 23.9
Histologyc LP 59 15.5 11.8 P=0.07
NS 257 27.8 15.3
MC 105 27.8 21.6
LD 9 33.3 od
Stage I 158 21.1 5.9 P<0.01
II 274 29.0 19.9
Symptoms A 356 25.1 17.5 P=0.06
B 76 30.9 6.6
aFor patients remaining in remission at 3 years; bLog-rank comparison of actuarial
relapse risk years 4-12; CTwo values missing; dOnly six patients- not included in log
rank analysis.















Figure 3 Actuarial relapse-free survival by st
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Other factors influencing the timing of relaps
Other prognostic factors known to influe
survival (Haybittle et al., 1985) were examin
their relevance to the timing of relapse. The
factors is shown in Table II, which show
relapse rate for each group at the end c
between 3 and 12 years for those in remission
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previously reported (Horwich et al., 1986
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On univariate analysis presentation with
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the risk of late relapse increased marginally fi
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Discussion
The management of patients with Hodgki
improved over the last two decades, due in
8/123 ments in radiotherapy, the introduction of combination
chemotherapy and improved staging techniques, together
with the identification of patients in whom the use of
combined modality therapy may enhance the chances of
29/187 cure. The influence of these factors was seen as the falling
risk of early and overall relapse rates over the two decades
studied in this paper. In clinically staged, radiotherapy-
treated patients early relapse was common, reflecting the
inadequacy of primary staging and treatment. The introduc-
tion of laparotomy staging reduced the risk of early relapse
through the detection of many cases with occult infradia-
phragmatic disease but the actuarial risk of late relapse in
those remaining in remission at 3 years remained unchanged.
The use of combined modality therapy in conjunction with
laparotomy staging in the majority of patients in the late
1970s reduced the risk of both early and late relapse.
Most recently, delineation of bad-risk prognostic factors
10 1'2 has led to a reduction in the use of laparotomy staging, with
combined modality therapy used electively in clinically
staged patients. Early relapse rates have been further reduced
age of platients but the risk of late relapse remains unchanged. This may be
vge
ra
than stage explained by the inclusion of more patients with occult stage
III disease in stage I or II groupings. In such patients
chemotherapy may induce a growth delay in occult disease
sufficient to delay relapse until three years or more after
treatment, a hypthesis also proposed by others (Weller et al.,
th radiotherapy 1976; De Vita et al., 1980). It is, however, striking that the
risk of late relapse has remained relatively constant as
its treated with overall survival has improved, suggesting the existence of a
ithin 6 years of subgroup of patients with indolent but resistant disease. The
at 4 years) in a influence of B symptoms and adverse histology on the timing
nt. The risk of of relapse could be explained by the association with
systemic treat- aggressive disease, leading to early relapse, while in patients
3% of those at without these features, the disease is likely to be more
ars, and did not indolent and therefore more likely to relapse late.
se in the same Our results were in contrast to the series reported by
.1% per year). Herman et al. (1985), in which the occurrence of late relapse
-treated patients was significantly associated with the nodular sclerosing histo-
d 20 years after logical subtype. The only association with histological sub-
type was that none of the relapsing patients with
lymphocyte-depleted histology did so after 2 years, although
we the total number of patients in this group (9) did not allow
statistical comparison. Additionally, in this present series late
nce relapse-free relapse was seen more commonly in stage II than stage I
led to determine patients in contrast to Herman et al. (1985), who found that
analysis of these stage I was significantly related to late relapse. There may be
vs the actuarial several explanations for these observations. Firstly, Herman
)f 3 years and et al. only compared early with late relapse rather than
at 3 years. The analysing relapse as a proportion of those at risk. Secondly,
elapse has been our series considered only stage I and stage II patients: the
) and was not inclusion of patients with more advanced disease might alter
the pattern of relapse. Thirdly, the Stanford series included
stage II (Figure patients treated up to 1979; the current series included
symptoms were patients up until 1983, in whom more recent advances in
ts remaining in management may have influenced the timing of relapse.
published data The majority of patients with Hodgkin's disease remaining
nt excess of late free of relapse for 3 years after treatment may be expected to
osing histology; be cured. However, this study reveals that at least one-
rom lymphocyte quarter of relapses occur after this time; the actuarial risk of
ixed cellularity relapse between 3 and 12 years was 15.7%. What is striking
patients with is that the risk of late relapse has remained unchanged over
vithin 3 years, the past two decades although overall relapse rates have
relapses did not fallen.
gical types. The The only reduction in the risk of late relapse with
f stage II rather changing management policies was noted when combined
dent prognostic modality therapy was used in conjunction with laparotomy-
analysis. staging, by which occult stage III cases would be excluded
and all disease treated with both chemotherapy and irradia-
tion. Justification of such aggressive approach to reduce late
relapse rates might be difficult because of the added mor-
bidity entailed. Careful follow-up of patients in the risk
categories described above beyond the 3 years conventionally
in's disease has accepted as cure continues to be required to detect late
part to refine- relapse.
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